Device Trial Radar · NCT07356089
Twiist Postmarket Surveillance Study for Type 1 Diabetes
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,875
Planned (sponsor's estimate)
Start
Dec 9, 2025
Primary completion
May 1, 2027
Study completion May 1, 2028
Sponsor
- Lead sponsor
- Deka Research and DevelopmentNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Jaeb Center for Health Research
- First posted
- Jan 21, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this surveillance study is to collect real-world data on adults and youth with type 1 diabetes (T1D) using twiist(TM) for insulin delivery.
Conditions
- Type 1 Diabetes (T1D)
- Type 1 Diabetes Mellitus
Interventions
twiist Automated Insulin Delivery SystemDevice
twiist(TM) system includes a novel insulin pump, a CGM sensor, and the glycemic-control algorithm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severe hypoglycemia eventsTime frame: From enrollment to the end of participation at 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jaeb Center for Health Research
Tampa, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.